Tax Bill Drops Bomb on Alimony Payments
4 Huge Opportunities to Beat the Tax Bill
The Tax Cuts and Jobs Act: An Advisors Guide
A confluence of global synchronized growth, accommodative money policy and positive political reform in Europe should lead to continued double-digit returns for foreign equities in 2018, according to the Northern Trust CIO Bob Browne.
“We feel positive on European growth, Abenomics is certainly working in Japan, and we’re not expecting a hard landing in China,” Browne told ThinkAdvisor, adding that the two largest economies in the world, the United States and China, will continue to do “quite well.” The Northern Trust forecast for equity returns in 2018 is 13.4% in developed markets outside the U.S., mostly in European markets and Japan, and 13.1% return for emerging markets.
(Related: Jeremy Grantham: ‘Be Brave’ and Invest in Emerging Markets)
Through Dec. 18, France’s Cac 40 Index is up about 20%, while Germany’s Dax Index is up nearly 25%. In comparison, the S&P 500 is up almost 19%, Japan’s Nikkei 225 is up nearly 17%, while the United Kingdom’s FTSE is only up 5% for 2017.
Top Growth Stocks For 2018: Franklin Resources, Inc.(BEN)
- [By Craig Jones]
Jim Strugger recommended on Bloomberg Markets a long position in Franklin Resources, Inc. (NYSE: BEN).
He said the company is in the assets management sector and he added that the market is probably getting into the period of higher dispersion, which is usually favorable for active managers. Speaking on the positive catalysts for the stock, Strugger said Franklin Resources is going to benefit from the cash repatriation.
- [By WWW.THESTREET.COM]
Franklin Resources (BEN) : “I’d rather see you in Morgan Stanley (MS) or E*TRADE Financial (ETFC) .”
Kinder Morgan (KMI) : “They are OK now, but there are better ones.”
Top Growth Stocks For 2018: Aluminum Corporation of China Ltd(ACH)
- [By Lisa Levin]
Wednesday afternoon, the basic materials shares climbed by 1.09 percent. Meanwhile, top gainers in the sector included Olympic Steel, Inc. (NASDAQ: ZEUS), up 7 percent, and Aluminum Corp. of China Limited (ADR) (NYSE: ACH), up 7 percent.
Top Growth Stocks For 2018: Silicon Laboratories Inc.(SLAB)
- [By Lisa Levin]
Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia